Table 2.

Summary of menstrual blood loss outcomes.

Study	Time	Alkaline haematin method†		P value	PBAC score†		P value	Percentage change from baseline		Superior
		LNG-IUS	Medical therapy		LNG-IUS	Medical therapy		LNG-IUS	Medical therapy
Irvine et al. [36]	Baseline	105 (82–780)	120 (82–336)	0.56	–	–		94%	87%	Equal‡
	3 months	6 (0–284)	20 (4–137)		—	–
Reid et al. [38]	Baseline	122 (81–375)	121 (85–389)	<0.001	240 (91–545)	233 (77–469)	<0.001	79%	23%	LNG-IUS
	Cycle 6	5 (0–45)	100 (46–168)		25 (0–402)	159 (50–307)
Endrikat et al. [18]	Baseline	–	–	–	228	290	0.002	83%	68%	LNG-IUS
	12 months	–	–		13	72
Kaunitz et al. [19]	Baseline	148.0 (68.3–431.4)	154.2 (63.4–456.0)	<0.001	–	–		70.8%	21.5%	LNG-IUS
	Cycle 6	7.1 (0–1435.6)	121.5 (0–437.7)		–	–
Shabaan et al. [20]	Baseline	300.0±150.1	274.3±142.6	<0.001	306.7±131.8	323.8±97.3	<0.001	87.4%	35.0%	LNG-IUS
	12 months	44.4±34.9	118.2±75.0		31.6±35.1	273.0±238.4
Küçük et al. [17]	Baseline	–	–	–	287±57	284±50	<0.05	–	–	LNG-IUS§
	6 months	–	–		77±41	146±21
	Baseline	–	–	–	287±57	230±36	<0.05	–	–	LNG-IUS¶
	6 months	–	–		77±41	154±30

LNG-IUS – levonorgestrel-releasing intrauterine system; PBAC – pictorial bleeding assessment chart.

^†Data are expressed as median, median (range) or mean ± standard deviation;

^‡LNG-IUS versus norethisterone;

^§LNG-IUS versus depot medroxyprogesterone acetate;

^¶LNG-IUS versus oral medroxyprogesterone acetate.